Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
Articolo
Data di Pubblicazione:
2021
Abstract:
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion of patients achieve long-term survival, about one-third of patients experience detrimental survival outcomes, including early death, hyperprogression, and fast progression. The impact of clinical factors on early progression (EP) development has not been widely explored. Methods: We designed a retrospective, multicenter study involving five Italian centers, in patients with metastatic NSCLC with PD-L1 ≥ 50%, treated with Pembrolizumab in a 1L setting. EP was defined as a progressive disease within three months from pembrolizumab initiation. Baseline clinical factors of patients with and without EP were collected and analyzed. Logistic regression was performed to identify clinical factors associated with EP and an EP prognostic score was developed based on the logistic model. Results: Overall, 321 out of 336 NSCLC patients tre...
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Corticosteroid; Detrimental effect; Immunotherapy; NSCLC; Pleural metastasis; Prognosis;
Elenco autori:
Passaro, Antonio; Novello, Silvia; Giannarelli, Diana; Bria, Emilio; Galetta, Domenico; Gelibter, Alain; Reale, Maria Lucia; Carnio, Simona; Vita, Emanuele; Stefani, Alessio; Pizzutilo, Pamela; Stati, Valeria; Attili, Ilaria; de Marinis, Filippo
Link alla scheda completa:
Pubblicato in: